𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gene therapy clinical trials worldwide to 2007—an update

✍ Scribed by Michael L. Edelstein; Mohammad R. Abedi; Jo Wixon

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
574 KB
Volume
9
Category
Article
ISSN
1099-498X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

To date, over 1340 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. In 1997 we set up a database to bring together global information on gene therapy clinical trials as comprehensively as possible. The data are compiled and regularly updated from official agency sources, published literature, conference presentations and posters and from information kindly provided by investigators or trial sponsors themselves.

This review updates our descriptive overview of the data in 2004 1, presenting our analysis of the clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of July 30 2007, we have stored entries on 1309 trials in 28 countries. We have analyzed the geographical distribution of trials, the disease indications (or other reasons) for trials, the proportions to which different vector types are used, and which genes have been transferred. Details of the analyses presented, and our interactive, searchable database can be found on The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Gene therapy clinical trials worldwide 1
Gene therapy clinical trials worldwide 1989–2004—an overview
✍ Michael L. Edelstein; Mohammad R. Abedi; Jo Wixon; Richard M. Edelstein 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract In 1989, Rosenberg __et al.__ performed the first human gene therapy trial when they used a retrovirus to introduce the gene coding for resistance to neomycin into human tumor‐infiltrating lymphocytes before infusing them into five patients with advanced melanoma. This study demonstrate

Gene transfer and therapy clinical trial
Gene transfer and therapy clinical trials – update. Part I: Countries, Diseases, Clinical trial phases, Routes of administration
✍ Thomas Valère 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 2 views

Part I\*: Countries, Diseases, Clinical trial phases, Routes of administration ## Countries Countries where clinical trials are being performed or have been approved Gene therapy trials have now been initiated on all ®ve continents but the large majority of trials are being performed in the USA

Gene transfer and therapy clinical trial
Gene transfer and therapy clinical trials – update. Part 2: gene delivery systems used and genes transferred
📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

Part 2\*: Gene Delivery Systems Used and Genes Transferred Delivery systems Gene delivery systems are based either on physicochemical methods or on biological methods (or a combination of the two). Gene Delivery systems used in humans to date are: Physico-chemical methods Biological methods Gene gun

An inventory of shedding data from clini
An inventory of shedding data from clinical gene therapy trials
✍ Ellen A. M. Schenk-Braat; Marjolein M. K. B. van Mierlo; Gerard Wagemaker; Chris 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract Viruses are the most commonly used vectors for clinical gene therapy. The risk of dissemination of a viral vector into the environment via excreta from the treated patient, a phenomenon called shedding, is a major safety concern for the environment. Despite the significant number of cli

From the laboratory bench to the patient
From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells
✍ Antonio Giordano; Umberto Galderisi; Ignazio R. Marino 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract Mesenchymal Stem Cells (MSCs) are non‐hematopoietic multi‐potent stem‐like cells that are capable of differentiating into both mesenchymal and non‐mesenchymal lineages. In fact, in addition to bone, cartilage, fat, and myoblasts, it has been demonstrated that MSCs are capable of differe

Completion of premaintenance phases in t
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma : An important variable to be considered in clinical trial designs
✍ Bart Barlogie; Jeff Haessler; Mauricio Pineda-Roman; Elias Anaissie; Frits van R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB

## Abstract ## BACKGROUND. Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance. ## METHODS. The impact of completion versus noncompletion of intended